AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.430

-0.220-1.41%

Volume:88.10K

Turnover:1.36M

Market Cap:5.23B

PE:115.84

High:15.590

Open:15.390

Low:15.340

Close:15.650

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.76

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.67

PE(LYR):-523.67

Loading ...

Overview Company News Filings

Telix Says Thyroid Cancer Therapy Candidate Shows Encouraging Disease Control, Acceptable Safety Profile in Real-World Data Review

MT Newswires Live

3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look

Simply Wall St.

3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction

Simply Wall St.

U.S. Stocks on the Move-duke Robotics, Tesla, Hasbro

U.S. Stocks on the Move-utz Brands, Tutor Perini, Tripadvisor

Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says

MT Newswires Live

3 Australian Growth Stocks Trading Below Fair Value With Strong Insider Backing

Simply Wall St.

Australia's Telix Pharmaceuticals Gains on Upbeat Quarterly Revenue

Telix Q2 Revenue Us$247m, Strong Momentum and Pipeline Progress

THOMSON REUTERS

Telix Appoints Three New Non-executive Directors to Expanded Board

Telix Expects Fy2026 Revenue and Other Income Above US$1 Billion, Tracks Upper End of Guidance Range

Telix Pharmaceuticals Ltd - Telix Expects FY 2026 Revenue and Other Income to be in Excess of US$1 Bln

THOMSON REUTERS

Telix Doses First Patient in Phase 3 Luteon Trial of Tlx250-tx for Renal Cancer

THOMSON REUTERS

3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look

Simply Wall St.

3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction

Simply Wall St.

Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan

MT Newswires Live

Telix Pharmaceuticals Opens Radiopharmaceutical Research, Manufacturing, Treatment Facility in Melbourne

MT Newswires Live

3 ASX Growth Stocks Backed By Insiders That Could Reward Patient Investors

Simply Wall St.

Telix Reports First Patients Dosing in Prostate Cancer Trial

MT Newswires Live

Citi Sees Positive Catalysts for Telix Pharmaceuticals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/TLX.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.43,"timestamp":1788135202848,"preClose":15.65,"halted":0,"volume":88100,"delay":0,"changeRate":-0.014057507987220488,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13320206675045385,"marketStatus":"Trading","change":-0.22,"latestTime":"08-31 10:13:25 AEST","open":15.39,"high":15.59,"low":15.34,"amount":1360289,"amplitude":0.015974,"askPrice":15.43,"askSize":437,"bidPrice":15.41,"bidSize":103,"shortable":3,"etf":0,"ttmEps":0.13320206675045385,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788156000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":15.65,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.757849,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.65,"auctionPrice":15.39,"auctionVolume":19942,"auctionTime":1788134344611,"referenceTime":1787913003093,"auction":1,"marketStatus":"盘前竞价","timestamp":1788134344611}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029465,"volumeRatio":1.757849,"shares":338721355,"dividePrice":0,"high":15.59,"amplitude":0.015974,"preClose":15.65,"low":15.34,"week52Low":8.26,"pbRate":"7.67","psRate":"4.20","week52High":18.32,"institutionHeld":0,"latestPrice":15.43,"committee":-0.618519,"eps":0.13320206675045385,"divideRate":0,"volume":88100,"delay":0,"ttmEps":0.13320206675045385,"open":15.39,"prevYearClose":11.2,"prevWeekClose":15.65,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":16.16,"twentyDayClose":14.28,"sixtyDayClose":13.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653030167","title":"Telix Says Thyroid Cancer Therapy Candidate Shows Encouraging Disease Control, Acceptable Safety Profile in Real-World Data Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2653030167","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653030167?lang=en_us&edition=fundamental","pubTime":"2026-07-24 12:07","pubTimestamp":1784866058,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Friday longterm clinical outcomes in an investigatorled study evaluating fibroblast activation protein -targeted therapy candidate, TLX400Tx, showed disease control rate of 80% based on the Response Evaluation Criteria in Solid Tumors, an acceptable safety profile, and preliminary efficacy signals in medullary thyroid cancer.A retrospective analysis of real-world data demonstrated a partial response rate of 33% and stable disease in 47% of patients, the company said in a statement. The median progression-free survival was 26 months, and the median overall survival was 42 months, with no dose-limiting toxicities detected.The outcomes from the study of 17 evaluable patients with progressive, locally advanced, or metastatic medullary thyroid carcinoma were published in the European Journal of Nuclear Medicine and Molecular Imaging  Research.Most of the patients had received prior systemic therapies, Telix said. They received a median of five cycles of TLX400-Tx","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653072656","title":"3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2653072656","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653072656?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:28","pubTimestamp":1784809691,"startTime":"0","endTime":"0","summary":"With inflation concerns, higher bond yields, and energy driven price pressures in focus, many investors are looking for stocks where management and analysts are aligned on growth potential. Our Fast Growing Stocks With High Insider Ownership screener highlights companies where insiders hold substantial stakes and outlooks are described as optimistic, which can signal confidence in the business plan and future prospects. In this article, you will see 3 stocks from this screener that stand out...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["E200.AU","IMLC.AU","QFN.AU","BK7145","BEAR.AU","QRE.AU","BK4139","EIGA.AU","VAS.AU","XJO.AU","GIVE.AU","STW.AU","OZR.AU","DACE.AU","IIGF.AU","IISV.AU","XKO.AU","IOZ.AU","XAO.AU","BBOZ.AU","BK7067","VAP.AU","GLF.AU","OZF.AU","TLX","GEAR.AU","TLX.AU","BK7104","PDI.AU","SLF.AU","ZYAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653759165","title":"3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759165","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653759165?lang=en_us&edition=fundamental","pubTime":"2026-07-22 14:24","pubTimestamp":1784701486,"startTime":"0","endTime":"0","summary":"With inflation pressures tied to energy markets, mixed growth signals across regions, and central banks keeping a close eye on every data point, many investors are looking for stocks where management has real skin in the game. The Fast Growing Stocks With High Insider Ownership screener focuses on companies that analysts and insiders both view with optimism, which can help align leadership decisions with shareholder interests. In this article, you will see three stocks from this screener that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["STW.AU","TLX.AU","BK4139","ZYAU.AU","BK7104","BEAR.AU","BK7067","OZR.AU","DACE.AU","EIGA.AU","IIGF.AU","GEAR.AU","VAP.AU","IISV.AU","GIVE.AU","QFN.AU","BBOZ.AU","VAS.AU","BK7145","QRE.AU","XAO.AU","XKO.AU","XJO.AU","IOZ.AU","IMLC.AU","E200.AU","TLX","PDI.AU","SLF.AU","OZF.AU","GLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653034201","title":"U.S. Stocks on the Move-duke Robotics, Tesla, Hasbro","url":"https://stock-news.laohu8.com/highlight/detail?id=2653034201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653034201?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:33","pubTimestamp":1784651615,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Duke Robotics, Tesla, HasbroWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL6N43N0ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLGB","BHP.AU","VIVKD","VVX","MGY","RPT","FCX","WDC","MBLY","CVX","BANC","CDE","PKE","RIO.AU","ZION","TSLA","LITB","LSTA","INTC","LLY","MMM","AU","EOG","GPC","MSCI","TPC","HL","TPL","ZYBT","XOM","ADBE","HAL","LBGJ","TLX.AU","RSPG","NEM","GM","RIO.UK","TRIP","VIVK","AGIO","AGMI","DUKR","EFX","HAS","SCCO","UTZ","DHR","FLUT","TER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653120841","title":"U.S. Stocks on the Move-utz Brands, Tutor Perini, Tripadvisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2653120841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653120841?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:27","pubTimestamp":1784640424,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Utz Brands, Tutor Perini, TripadvisorWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL6N43N0ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU2108987350.USD","IE00B19Z3581.USD","LU1223083913.SGD","LU0106261372.USD","LU2168563687.JPY","CURE","SG9999014914.USD","BK4077","LU1496350502.SGD","IE00BJJMRY28.SGD","LLYX","SG9999001176.USD","LU0208291251.USD","SLVR","LU0198837287.USD","LU0130103400.USD","IE00BQXX3D17.EUR","IE00BJLML261.HKD","WDNA","LU1232071149.USD","NVO","LU1366333091.USD","LU0320765992.SGD","LU0964807845.USD","LU0345780281.USD","BK4599","FMED","LU1267930813.SGD","LU1992135399.USD","RXL","BK4581","BK4213","AGMI","BK4231","LU0672654240.SGD","BK4121","BK7507","SLVP","LU1861214812.USD","TRIP","LU1861219969.SGD","BANC","LU2750360641.GBP","LU0640476718.USD","HAS","LU0058720904.USD","BK4206","LU0158827948.USD","LU1064131342.USD","LU2168564149.EUR","LU0466842654.USD","MGY","LU1061106388.HKD","IE000M9KFDE8.USD","LLII","LU2168564495.EUR","MEDI","SGXZ81514606.USD","LU0823434740.USD","LU1057294990.SGD","LU0158827781.USD","LU2211814178.USD","LU0786609619.USD","LU0006061336.USD","IE00BQXX3C00.GBP","LU2237443549.SGD","BK4585","LU1150488135.SGD","IE0009355771.USD","LU0345780950.USD","LU2498475776.HKD","LU1366192091.USD","LU0566484027.USD","LU2756315664.SGD","LU0820561818.USD","LU2237438978.USD","IE00B3S45H60.SGD","BK4516","LU0122379950.USD","IE00B19Z3B42.SGD","LU0238689110.USD","LU1035775433.USD","LU0266013472.USD","LU0316494557.USD","LU1093756168.USD","BK4123","BK4555","BK4570","GMET","LU2361044865.SGD","TPC","LU0792757196.USD","SG9999004303.SGD","EXK","CDE","LU0345770308.USD","ELIS","IE00B4R5TH58.HKD","LU2324357040.USD","LU2756315318.SGD","LU0572108347.SGD","LU0528227936.USD","LU0345780521.USD","LU1894683264.USD","CANC","LU2065171311.SGD","BK7095","LU2264538146.SGD","BK4015","BK4007","LU0174119429.USD","IE00BKVL7J92.USD","LU2237443622.USD","IE00BZ9MQY76.HKD","LU2462157665.USD","IE00BFTCPJ56.SGD","SG9999014880.SGD","LU0345781412.USD","PICK","MHIP","PSCE","BK4212","BK4533","LU1150488218.USD","LU1366334578.USD","LU2106854487.HKD","LU0612318385.USD","AWAY","LU1894683348.USD","LU0683600562.USD","LU2602419157.SGD","LU0006306889.USD","LU2417539215.USD","LU2361045086.USD","SG9999001176.SGD","SG9999013999.USD","LU0162691827.USD","LU0029864427.USD","IE00BQXX3F31.USD","LU0471298694.HKD","SETM","SG9999002521.SGD","LU0211331839.USD","BK4512","LU2089283258.USD","LU2746668461.USD","IE00B19Z9Z06.USD","SG9999015978.USD","SG9999015952.SGD","IE0004445015.USD","LU0061475181.USD","LU1267930730.SGD","LU2125910336.SGD","SGXZ31699556.SGD","BK4574","LU2112291526.USD","LU0788109048.HKD","LU2360106947.USD","GDXJ","LU1868837300.USD","GDX","LU0175139822.USD","LU0320765059.SGD","LU1720051108.HKD","VHT","NVOX","TLX.AU","FTXH","LU1988902786.USD","IE00BKDWB100.SGD","LU2237443895.HKD","IE00BWXC8680.SGD","BK4588","SG9999017495.SGD","GDOC","LU0225283273.USD","IE00B7KXQ091.USD","LU2028103732.USD","BK4589","LU2357627491.SGD","LU1223082519.USD","LU2211815571.USD","IE00BJT1NW94.SGD","BK4110","LU1291159041.SGD","LU0882574055.USD","LU2272731600.USD","LU0889565916.HKD","LU0203201768.USD","SLJY","LU0648000940.SGD","LU2491049909.HKD","LU0943347566.SGD","FCXG","IE0001KFT4U8.USD","NVOH","IE00B2B36J28.USD","BK4017","LU0075056555.USD","BK4190","LU2213496289.HKD","SGXZ99366536.SGD","BK4157","IE0002270589.USD","LU1868836914.USD","LU0312595415.SGD","LU1223082196.USD","LU1791710582.SGD","LU1868836757.USD","LU0330918003.SGD","LU0791590937.USD","HL","LU0432979614.USD","LU2237443978.SGD","LU2746668974.SGD","MMM","LU1791710400.SGD","GB00BDT5M118.USD","LU0456854461.SGD","LU1201861165.SGD","IE00BJJMRZ35.SGD","LU0050427557.USD","LU2244417387.USD","IE00BZ1G4Q59.USD","LU2491050071.SGD","LU0300736492.USD","LU1023059493.AUD","LU0096364046.USD","LU1623119135.USD","SILJ","LU0353189763.USD","FMTL","IE00BK4W5M84.HKD","FHLC","LU0132412106.USD","LU1974910355.USD","LU0054578231.USD","BK4534","LLY","BK4596","IE00B1XK9C88.USD","LU2168564222.USD","LU0980610538.SGD","SGDM","LU0289960550.SGD","LU1267930573.SGD","IE00B4JS1V06.HKD","LU2125909247.SGD","IE00BFSS8Q28.SGD","BK4211","LU1883866441.USD","LU1923622614.USD","RPT","LU0511384066.AUD","LU0109394709.USD","LU2265009873.SGD","BK4532","LU0654597011.USD","LU0300736062.USD","BK4080","LU0456855351.SGD","LU2896262040.SGD","BK4566","LU0274383776.USD","LU0266512127.USD","BK4129","LU2360107325.USD","LU0289739343.SGD","IYH","LU0256863902.USD","LU0859254822.USD","IE00B775H168.HKD","LU0889566641.SGD","LU1917777945.USD","LU0130518102.USD","IE0005OL40V9.USD","LU0630314457.HKD","LU2272731782.SGD","SG9999002224.SGD","LU2065169927.USD","RIO.AU","SG9999015986.USD","LU0385154629.USD","LU0820562030.AUD","IHE","THNR","SG9999014906.USD","ILDR","SLVX","LU0823434583.USD","LU2357305700.SGD","BK4139","LU1430597077.USD","LU0130102774.USD","LU2468319806.SGD","OZEM","LU2111349929.HKD","SGXZ51526630.SGD","LU2462611646.USD","SG9999002232.USD","HRTS","VVX","LU1804176565.USD","LU0266512473.USD","PJP","LLYZ","LU0107464264.USD","LU2552382132.HKD","LU2552382215.SGD","LU1280957306.USD","IE00BN29S564.USD","BHP.AU","LU0210536198.USD","LU1720051017.SGD","LU0787776722.HKD","AGNG","DHR","IE0002141913.USD","LU0094547139.USD","LU0097036916.USD","SG9999014898.SGD","LU0689472784.USD","LU1989771016.USD","PPH","LU1069344957.HKD","LU2023250330.USD","LU2361044949.HKD","IE00B1BXHZ80.USD","JDOC","LU1145028129.USD","LU2065170008.USD","SG9999018857.SGD","LU1992135472.HKD","IE00B7SZLL34.SGD","LU2023250504.SGD","EFX","ICOP","LU1127390331.HKD","LU0823416689.USD","LU0128525929.USD","IE00BKPKM429.USD","LU0323591593.USD","LU0072461881.USD","TRUH","LU0256863811.USD","LU1814569148.SGD","LU0070302665.USD","LU2355687059.USD","LU0109391861.USD","LU0354030511.USD","BK4099","AGIO","LU2462591350.SGD","LU1878469433.USD","GOAU","LU0882574139.USD","IE00B775SV38.USD","MBLY","COPP","LU1868837136.USD","LU1559883803.SGD","LU2236285917.USD","LU2491050154.USD","LU2087625088.SGD","IE00BK4W5L77.USD","LU1548497426.USD","SG9999018865.SGD","LU0354030438.USD","EMET","LU0289961442.SGD","LU0072463663.USD","LU1923621640.USD","IE00B894F039.SGD","LU0187121727.USD","LU0278409577.USD","AUAU","SCCO","LU0130517989.USD","LU1868836591.USD","TMED","LU2237443465.HKD","TRUM","LU0114720955.EUR","LU0203202063.USD","LU0788109121.HKD","LU0477156797.USD","ZION","LU0708994859.HKD","BK7067","LU0471298777.SGD","LU1551013342.USD","LU1712237335.SGD","LU2168564065.EUR","LU0612318971.USD","BK4504","MEDX","BK4124","SG9999015945.SGD","SIL","IXJ","LU2456880835.USD","SGXZ57979304.SGD","LU0708995401.HKD","LU2063271972.USD","SGXZ23171101.USD","IE00BFSS7M15.SGD","LU2552382058.USD","LU2471134796.USD","BK4187","GM","LU1629891620.HKD","LU0353189680.USD","COPA","HLXX","IE00B19Z9P08.USD","LU0345770993.USD","LU0234572021.USD","LU2471134879.HKD","LU2750360997.AUD","LU0133085943.USD","LU1323610961.USD","LU1551013425.SGD","WPM","LU0157215616.USD","UTZ","LU0079474960.USD","LU1201861249.SGD","LU2461242641.AUD","LU0289739699.SGD","LU0417517546.SGD","LU2125909593.SGD","LU0648001328.SGD","XME","COPX","LU0505663152.USD","LU2237443382.USD","BK7511","LU2065171402.SGD","BK4561","LU1023059063.AUD","LU0154236417.USD","IE0004445239.USD","LU2471134952.CNY","LU1366334651.USD","XLV","LU2023251221.USD","BK4559","LU1983299246.USD","BK4210","LU0791591158.USD","EART","LU2471134523.USD","IE00BJJMRX11.SGD","LU0310800379.SGD","LU0820561909.HKD","LU2089984988.USD","FCX","LU1093756325.SGD","LU2089284900.SGD","LU0477156953.USD","LU2125910179.SGD","ELIL","LU2271345857.HKD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653322184","title":"Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322184","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653322184?lang=en_us&edition=fundamental","pubTime":"2026-07-21 14:29","pubTimestamp":1784615387,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  stands to deliver meaningful investment upside and gain significant market share if it can secure regulatory approval for products in the development pipeline, Jefferies said in a Tuesday note.The company launched a prospective phase 3 study to evaluate TLX250-Tx as a potential radiotherapy for relapsed or recurrent clear cell renal cell carcinoma, with the first part of the study expected to enroll up to 40 patients.Following the progression to phase 3, Jefferies' risk-weighting for the trial increased to around 61% from about 21%, while the net present value for the opportunity moved to AU$2.13, the investment firm said.Jefferies raised its full-year 2026 net profit after tax forecast for Telix Pharmaceuticals to $10.6 million from $5.1 million after the company reported second-quarter revenue of $247 million. Telix also guided for 2026 operating revenue to be toward the top end of its $950 million to $970 million forecast range.The equity research firm maintai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653226016","title":"3 Australian Growth Stocks Trading Below Fair Value With Strong Insider Backing","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653226016?lang=en_us&edition=fundamental","pubTime":"2026-07-21 12:51","pubTimestamp":1784609487,"startTime":"0","endTime":"0","summary":"Fast growing stocks with high insider ownership can be especially interesting when markets are wrestling with questions around inflation, interest rates and geopolitical risk. While oil prices, central bank decisions and mixed growth signals pull headlines in different directions, investors often look for companies where management and insiders are strongly aligned with shareholders and where growth potential is supported by optimistic analyst and internal views. This article highlights 3...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-trading-below-fair-value-with-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-trading-below-fair-value-with-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GEAR.AU","OZF.AU","TLX","XAO.AU","ZYAU.AU","VAP.AU","BK7067","IIGF.AU","BBOZ.AU","E200.AU","VAS.AU","BEAR.AU","XJO.AU","PDI.AU","DACE.AU","TLX.AU","QFN.AU","GLF.AU","OZR.AU","QRE.AU","EIGA.AU","STW.AU","XKO.AU","BK7104","GIVE.AU","SLF.AU","IMLC.AU","BK4139","IISV.AU","IOZ.AU","BK7145"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653244962","title":"Australia's Telix Pharmaceuticals Gains on Upbeat Quarterly Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2653244962","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653244962?lang=en_us&edition=fundamental","pubTime":"2026-07-21 08:21","pubTimestamp":1784593304,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals gains on upbeat quarterly revenue** Shares of Telix PharmaceuticalsTLX.AXrise as much as 4.2% to A$15.73, their largest intraday pct jump since July 6** Biopharm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL4N43N00G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653124146","title":"Telix Q2 Revenue Us$247m, Strong Momentum and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2653124146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653124146?lang=en_us&edition=fundamental","pubTime":"2026-07-21 07:31","pubTimestamp":1784590302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUAWQTTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653241391","title":"Telix Appoints Three New Non-executive Directors to Expanded Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2653241391","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653241391?lang=en_us&edition=fundamental","pubTime":"2026-07-21 06:48","pubTimestamp":1784587693,"startTime":"0","endTime":"0","summary":"Telix appoints three new non-executive directors to expanded boardTelix appointed three non-executive directors, effective May 11, 2026: David Gill, Maria Rivas, MD, William Jellison.Disclaimer:This n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLb96KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653524909","title":"Telix Expects Fy2026 Revenue and Other Income Above US$1 Billion, Tracks Upper End of Guidance Range","url":"https://stock-news.laohu8.com/highlight/detail?id=2653524909","media":"Reuters","labels":["corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653524909?lang=en_us&edition=fundamental","pubTime":"2026-07-21 06:37","pubTimestamp":1784587022,"startTime":"0","endTime":"0","summary":"Telix expects FY2026 revenue and other income above US$1 billion, tracks upper end of guidance rangeTelix expects FY 2026 revenue and other income to exceed US$1 billion, tracking at the upper end of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL3j3hnB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4139","LU2237438978.USD","LU0114720955.EUR","IBB","BK7067","LU0053666078.USD","LU0109394709.USD","LU0823434740.USD","LU1974910355.USD","LU0889565916.HKD","LU2023250504.SGD","LU0823416689.USD","LU1917777945.USD","LU0882574055.USD","LU0320765992.SGD","LU0289739699.SGD","LU2362540622.SGD","LU2468319806.SGD","BK4585","IBBQ","LU2106854487.HKD","TLX.AU","BBH","LU0823434583.USD","LU2089984988.USD","LU2362541273.HKD","REGN","LU2362541513.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653249248","title":"Telix Pharmaceuticals Ltd - Telix Expects FY 2026 Revenue and Other Income to be in Excess of US$1 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2653249248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653249248?lang=en_us&edition=fundamental","pubTime":"2026-07-21 06:27","pubTimestamp":1784586435,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M11P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653524616","title":"Telix Doses First Patient in Phase 3 Luteon Trial of Tlx250-tx for Renal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653524616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653524616?lang=en_us&edition=fundamental","pubTime":"2026-07-21 05:00","pubTimestamp":1784581200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA2WC9JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652250486","title":"3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2652250486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652250486?lang=en_us&edition=fundamental","pubTime":"2026-07-20 03:20","pubTimestamp":1784488812,"startTime":"0","endTime":"0","summary":"With inflation readings softening in several major economies, bond yields pulling back from recent highs and energy prices back in focus, many investors are looking for growth stories where management has real skin in the game. The Fast Growing Stocks With High Insider Ownership screener targets companies that combine strong growth potential with leadership teams that are publicly optimistic about the outlook. In this article, you will see three stocks from that screener that stand out on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OZF.AU","GEAR.AU","BBOZ.AU","GLF.AU","IMLC.AU","STW.AU","E200.AU","BK7145","IIGF.AU","BK7104","BK7067","TLX.AU","QFN.AU","VAP.AU","PDI.AU","VAS.AU","ZYAU.AU","XAO.AU","BEAR.AU","XKO.AU","IOZ.AU","QRE.AU","XJO.AU","IISV.AU","OZR.AU","GIVE.AU","EIGA.AU","BK4139","DACE.AU","TLX","SLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652847265","title":"3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction","url":"https://stock-news.laohu8.com/highlight/detail?id=2652847265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652847265?lang=en_us&edition=fundamental","pubTime":"2026-07-17 12:57","pubTimestamp":1784264261,"startTime":"0","endTime":"0","summary":"With growth signals mixed across major economies and central banks pulling policy in different directions, many investors are looking for companies where management and outside analysts are broadly aligned on the outlook. That is exactly what the Fast Growing Stocks With High Insider Ownership screener focuses on, highlighting businesses with strong growth potential where insiders have meaningful skin in the game. This combination can help you focus on opportunities backed by both internal...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7145","IISV.AU","GLF.AU","BK7067","STW.AU","SLF.AU","QFN.AU","TLX","XJO.AU","XKO.AU","BK7104","EIGA.AU","GIVE.AU","IIGF.AU","DACE.AU","GEAR.AU","IOZ.AU","VAP.AU","IMLC.AU","ZYAU.AU","TLX.AU","E200.AU","BK4139","BBOZ.AU","VAS.AU","BEAR.AU","QRE.AU","OZR.AU","PDI.AU","OZF.AU","XAO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652473490","title":"Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652473490","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652473490?lang=en_us&edition=fundamental","pubTime":"2026-07-17 08:45","pubTimestamp":1784249142,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  has completed enrollment of 105 patients in its phase three registration study of TLX591-Px, a prostate cancer imaging agent, in Japan, according to a Friday statement by the company.The study will generate clinical data to support a new drug application submission to Japan's Pharmaceuticals and Medical Devices Agency, seeking approval for the use of the product in detecting metastatic lesions in patients with recurrent prostate cancer.The company's shares fell 2% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","BK7067","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651916490","title":"Telix Pharmaceuticals Opens Radiopharmaceutical Research, Manufacturing, Treatment Facility in Melbourne","url":"https://stock-news.laohu8.com/highlight/detail?id=2651916490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651916490?lang=en_us&edition=fundamental","pubTime":"2026-07-16 10:53","pubTimestamp":1784170381,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) opened a multi-million dollar radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, described as a \"first-of-its-kind\" Australian purpose-bu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651973204","title":"3 ASX Growth Stocks Backed By Insiders That Could Reward Patient Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651973204","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651973204?lang=en_us&edition=fundamental","pubTime":"2026-07-16 07:39","pubTimestamp":1784158745,"startTime":"0","endTime":"0","summary":"With inflation pressures moving differently across regions and interest rate expectations constantly in focus, many investors are looking for companies where both analysts and insiders see room for growth. The Fast Growing Stocks With High Insider Ownership screener targets exactly that. It highlights businesses that pair strong growth potential with management teams that have meaningful skin in the game. This combination can help align your interests with those running the company. In this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-asx-growth-stocks-backed-by-insiders-that-could-reward-pat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-asx-growth-stocks-backed-by-insiders-that-could-reward-pat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","TLX.AU","BK7067","ISBC","BK7104","BK4139","PDI.AU","BK7095","TLX","LIN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651967224","title":"Telix Reports First Patients Dosing in Prostate Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651967224","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651967224?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:58","pubTimestamp":1784149110,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said late Wednesday the first patients with metastatic hormone-sensitive prostate cancer have been dosed with TLX597-Tx in a phase 2 trial at St Vincent's Hospital in Sydney, Australia.The OPTIMAL-e trial will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA2 study which recently completed patient enrollment, the firm said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651748293","title":"Citi Sees Positive Catalysts for Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2651748293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651748293?lang=en_us&edition=fundamental","pubTime":"2026-07-15 07:06","pubTimestamp":1784070360,"startTime":"0","endTime":"0","summary":"2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\"  Dow Jones NewswiresJuly 14, 2026 19:06 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":198,"code":"91000000","status":"200"}]}}